Guilbert E, Laroche L, Borderie V
Service V, centre hospitalier national d'ophtalmologie des XV-XX, 28, rue de Charenton, 75571 Paris cedex 12, France.
J Fr Ophtalmol. 2011 May;34(5):331-48. doi: 10.1016/j.jfo.2011.02.001. Epub 2011 Apr 14.
Corneal graft rejection is the major cause of penetrating keratoplasty failure. It is a complex immunological process that involves recognition of alloantigens from the corneal graft by the host's immune system, leading to an efferent immune response against the graft. Each layer of the cornea can undergo rejection, endothelial rejection being the most severe form. In some cases, rejection will lead to corneal graft failure. Many donor- and host-related risk factors contribute to corneal graft rejection. Corticosteroid therapy, topical or systemic, is the gold-standard in the preventive and curative treatment of rejection. Other immunosuppressive agents are promising but require further evaluation. Early detection of rejection is essential to establish an aggressive treatment and reduce the risk of graft failure. Prevention of rejection is also based on tissue matching between donor and recipient. In high-risk patients, ABO compatibility decreases the risk of rejection. HLA compatibility could positively influence corneal graft survival in some cases.
角膜移植排斥反应是穿透性角膜移植术失败的主要原因。它是一个复杂的免疫过程,涉及宿主免疫系统识别来自角膜移植的同种异体抗原,从而引发针对移植体的传出免疫反应。角膜的每一层都可能发生排斥反应,内皮排斥是最严重的形式。在某些情况下,排斥反应会导致角膜移植失败。许多供体和宿主相关的危险因素都会导致角膜移植排斥反应。局部或全身使用皮质类固醇疗法是预防和治疗排斥反应的金标准。其他免疫抑制剂前景广阔,但需要进一步评估。早期发现排斥反应对于开展积极治疗和降低移植失败风险至关重要。预防排斥反应还基于供体和受体之间的组织配型。在高危患者中,ABO血型相容性可降低排斥反应的风险。在某些情况下,HLA相容性可能对角膜移植存活产生积极影响。